



THE CLAIMS ON FILE:

1. (Cancelled)
2. (Previously presented) The method of claim 5 wherein the pharmaceutical agent comprises a compound of formula (Ia):



wherein R⁹ is an alkyl group having 1-4 C atoms which, optionally, are substituted with halogen or replaced by halogen;
or a pharmaceutically acceptable salt thereof.


3. (Previously presented) The method of claim 5 wherein the pharmaceutical agent comprises a compound of formula (III):



or a pharmaceutically acceptable salt thereof.

4. (Cancelled)

5. (Previously presented) A method for a chemotherapeutic treatment of a neuropathy characterized by application to a patient in need thereof of from 1-100 mg/day of a pharmaceutical agent comprising a compound of formula (I):



in which

R¹=C₁₋₆alkyl, optionally substituted with halogen,

R²=hydrogen or C₁₋₄alkyl, optionally substituted with halogen or replaced with halogen,

R³=C₂₋₄alkyl, optionally substituted with halogen,

R⁴=SO₂NR⁵R⁶,

C₁₋₄alkyl, optionally substituted with NR⁵R⁶, CN, CONR⁵R⁶, CO₂R⁷, or halogen,

C₂₋₄-alkenyl, optionally substituted with NR⁵R⁶, SONR⁵R⁶, CONR⁵R⁶, CO₂R⁷, or halogen,

C₂₋₄-alkanoyl, optionally substituted with NR⁵R⁶, SONR⁵R⁶, CONR⁵R⁶, CO₂R⁷, or halogen,

R⁵ and R⁶, independent of one another, represent hydrogen or C₁₋₄alkyl, or, together with the nitrogen atom to which they are attached, represent a pyrrolidino, piperidino, morpholino, 4-(NR⁸)-1-piperazinyl or 1-imidazolyl ring which, optionally, may be substituted with one or two C₁₋₄alkyl groups,

R⁷=hydrogen or C₁₋₄alkyl, optionally, substituted with fluorine, and

R⁸=hydrogen, C₁₋₃alkyl, or hydroxy alkyl having 1-4 C atoms, or a pharmaceutically acceptable salt thereof,

wherein the neuropathy is selected from the group consisting of a peripheral diabetic polyneuropathy, gastroparesis, a degenerative neuropathy, a toxic neuropathy, and a metabolic neuropathy.

6. (Cancelled)

7. (Previously presented) The method of claim 5, wherein from 5-50 mg/day of said pharmaceutical agent is administered to a patient being treated.

8. (Previously presented) The method of claim 5, wherein from 25-50 mg/day of said pharmaceutical agent is administered to a patient being treated.

9. (Cancelled)

10. (Cancelled)

11. (Cancelled)


12. (Cancelled)

13. (Cancelled)

14. (Cancelled)

15. (Previously presented) The method of claim 5 wherein the neuropathy is selected from the group consisting of gastroparesis, a degenerative neuropathy, a toxic neuropathy, and a metabolic neuropathy.

16. (Previously presented) A method for a chemotherapeutic treatment of a peripheral diabetic polyneuropathy consisting of application to a patient in need thereof from 1-100 mg/day of a pharmaceutical agent comprising a compound of formula (I):



(I)

in which

R¹=C₁₋₆alkyl, optionally substituted with halogen,

R²=hydrogen or C₁₋₄alkyl, optionally substituted with halogen or replaced with halogen,

R³=C₂₋₄alkyl, optionally substituted with halogen,

R⁴=SO₂NR⁵R⁶,

C₁₋₄alkyl, optionally substituted with NR⁵R⁶, CN, CONR⁵R⁶, CO₂R⁷, or halogen,

C₂₋₄-alkenyl, optionally substituted with NR⁵R⁶, SONR⁵R⁶, CONR⁵R⁶, CO₂R⁷, or halogen,

C₂₋₄-alkanoyl, optionally substituted with NR⁵R⁶, SONR⁵R⁶, CONR⁵R⁶, CO₂R⁷, or halogen,

R⁵ and R⁶, independent of one another, represent hydrogen or C₁₋₄alkyl, or, together with the nitrogen atom to which they are attached, represent a pyrrolidino, piperidino, morpholino, 4-(NR⁸)-1-piperazinyl or 1-imidazolyl ring which, optionally, may be substituted with one or two C₁₋₄alkyl groups,

R⁷=hydrogen or C₁₋₄alkyl, optionally, substituted with fluorine, and

R⁸=hydrogen, C₁₋₃alkyl, or hydroxy alkyl having 1-4 C atoms, or a pharmaceutically acceptable salt thereof.